120404-76-4

Upstream product

• 108-20-3 di-isopropyl ether 
• 824-94-2 p-methoxybenzyl chloride 
• 120404-75-3 1-hydroxy-2-hydroxymethyl-5-(4-methoxybenzyloxy)-4-pyridone 
• 118679-90-6 2-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)pyridin-4(1H)-one 
• 118708-61-5 5-p-methoxybenzyloxy-2-hydroxymethyl-4-pyrone 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 

Downstream Products

• 1380110-44-0 C₄₅H₅₅N₇O₁₇S₂ 
• 1401528-98-0 C₁₆H₃₆N⁽¹⁺⁾*C₂₂H₂₀NO₇^(1-) 
• 1401529-11-0 C₂₈H₃₂N₆O₅ 
• 1380110-43-9 C₄₅H₅₅N₇O₁₄S 
• 1426097-03-1 C₂₅H₁₈Cl₂N₆O₆S 
• 1426097-15-5 (2-{[5-(2,6-dichlorophenyl)[1,2,4]triazin-3-ylamino]methyl}benzothiazol-5-yloxy)acetic acid 1,5-bis(4-methoxybenzyloxy)-4-oxo-1,4-dihydropyridin-2-ylmethyl ester 
• 120405-24-5 2-formyl-1,5-di-p-methoxybenzyloxy-4-pyridone 

Relevant academic research and scientific papers

Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with 4H-pyran-4-one and pyridin-4-one substitution in the C-14 side chain

A series of novel pleuromutilin derivatives with 4H-pyran-4-one and pyridin-4-one substitution in the C-14 side chain have been designed and synthesized. In vitro antibacterial activity evaluation showed that most of the derivatives exhibited potent antib

NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Pyridone-conjugated monobactam antibiotics with gram-negative activity

Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.

NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

Cephalosporin compounds and antibacterial agents

Cephalosporin compounds of the formula (I): STR1 wherein R1 and R2 may be the same or different and are a hydrogen atom or a lower alkyl group of 1-5 carbon atoms and A is a hydrogen atom or a nucleophilic compound residue or pharmacologically acceptable salts thereof have excellent antibacterial activity against Gram positive and Gram negative microorganisms.